Drug giant Bristol-Myers Squibb is the latest to feel the shockwave caused by the failure of a widely watched cancer immunotherapy nearly a month ago.
Xconomy has learned that Bristol (NYSE: BMY) is curtailing work on three late-stage studies testing an experimental cancer drug that it bought for $800 million three years ago.
The agent was an IDO inhibitor, part of a drug class considered a top contender to expand the limited reach of cancer immunotherapy. Earlier this month, epacadostat, an IDO inhibitor from Delaware biotech Incyte (NASDAQ: INCY), failed in combination with the FDA-approved pembrolizumab (Keytruda) in… Read more »
UNDERWRITERS AND PARTNERS